The effectiveness of oracin in enhancing the cytotoxicity of doxorubicin through the inhibition of doxorubicin deactivation in breast cancer MCF7 cells

Xenobiotica

Volumn 40, Issue 10, 2010, Pages 681-690

  Hanusova V ^a   Kralova V ^b   Schroterov L ^b   Trilecova L ^c   Pakostova A ^a   Skalov L ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c VETERINARY RESEARCH INSTITUTE   (Czech Republic)

Author keywords

Carbonyl reduction; cell proliferation; doxorubicin metabolizing enzymes; enzyme inhibition

Indexed keywords

CASPASE 8; CASPASE 9; DOXORUBICIN; ORACIN; OXIDOREDUCTASE;

ARTICLE; CANCER INHIBITION; CELL STRAIN MCF 7; CELL VIABILITY; CONTROLLED STUDY; CYTOSOL; CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL;

ANTIBIOTICS, ANTINEOPLASTIC; CASPASES; CELL LINE, TUMOR; DOXORUBICIN; ELECTRIC IMPEDANCE; ETHANOLAMINES; HUMANS; ISOQUINOLINES; OXIDOREDUCTASES;

EID: 77956574779     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2010.508821     Document Type: Article

References (37)

1. Adamcová M, Gersl V, Hrdina R, Melka M, Mazurová Y, Vávrová J, Palicka V, Kokstein Z. (1999). Cardiac troponin T as a marker of myocardial damage caused by antineoplastic drugs in rabbits. J Cancer Res Clin Oncol 125:268-274.
2. Appleyard MV, O'Neill MA, Murray KE, Paulin FE, Bray SE, Kernohan NM, Levison DA, Lane DP, Tompson AM. (2009). Seliciclib (CYC202, R-roscovitine) enhances the antitumor efect of doxo-rubicin in vivo in a breast cancer xenograft model. Int J Cancer 124:465-472.
3. Ax W, Soldan M, Koch L, Maser E. (2000). Development of daunoru-bicin resistance in tumour cells by induction of carbonyl reduction. Biochem Pharmacol 59:293-300.
4. Bae JY, Ahn SJ, Han W, Noh DY. (2007). Peroxiredoxin I and II inhibit H2O2-induced cell death in MCF-7 cell lines. J Cell Biochem 101:1038-1045.
5. Carlquist M, Frejd T, Gorwa-Grauslund M F. (2008). Flavonoids as inhibitors of human carbonyl reductase 1. Chem Biol Interact 174:98-108.
6. Carvalho C, Santos RX, Cardoso S, Correia S, Oliveira PJ, Santos MS, Moreira PI. (2009). Doxorubicin: the good, the bad and the ugly efect. Curr Med Chem 16:3267-3285.
7. Di Nicolantonio F, Mercer SJ, Knight LA, Gabriel FG, Whitehouse PA, Sharma S, Fernando A, Glaysher S, Di Palma S, Johnson P, Somers SS, Toh S, Higgins B, Lamont A, Gulliford T, Hurren J, Yiangou C, Cree IA. (2005). Cancer cell adaptation to chemotherapy. BMC Cancer 5:78.
8. Erenpreisa J, Cragg MS. (2001). Mitotic death: a mechanism of survival? A review. Cancer Cell Int 1:1.
9. Erlund I, Silaste ML, Alfthan G, Rantala M, Kesäniemi YA, Aro A. (2002). Plasma concentrations of the favonoids hesperetin, nar-ingenin and quercetin in human subjects following their habitual diets, and diets high or low in fruit and vegetables. Eur J Clin Nutr 56:891-898.
10. Fischer D, Seifert M, Becker S, Ludders D, Cordes T, Reichrath J, Friedrich M. (2007). 25-Hydroxyvitamin D3 1alpha-hydroxylase splice variants in breast cell lines MCF-7 and MCF-10. Cancer Genomics Proteomics 4:295-300.
11. Gavelová M, Hladíková J, Vildová L, Novotná R, Vondrácek J, Krcmár P, Machala M, Skálová L. (2008). Reduction of doxorubicin and oracin and induction of carbonyl reductase in human breast carcinoma MCF-7 cells. Chem Biol Interact 176:9-18.
12. Gersl V, Mazurová Y, Bajgar J, Melka M, Hrdina R, Palicka V. (1996). Lack of cardiotoxicity of a new antineoplastic agent, a synthetic derivative of indenoisochinoline: comparison with daunorubicin in rabbits. Arch Toxicol 70:645-651.
13. Gonzalez-Covarrubias V, Kalabus JL, Blanco JG. (2008). Inhibition of polymorphic human carbonyl reductase 1 (CBR1) by the cardio-protectant favonoid 7-monohydroxyethyl rutoside (monoHER). Pharm Res 25:1730-1734.
14. Kaiserová H, Simunek T, van Der Vijgh WJ, Bast A, Kvasnicková E. (2007). Flavonoids as protectors against doxorubicin cardiotox-icity: role of iron chelation, antioxidant activity and inhibition of carbonyl reductase. Biochim Biophys Acta 1772:1065-1074.
15. Kassner N, Huse K, Martin HJ, Gödtel-Armbrust U, Metzger A, Meineke I, Brockmöller J, Klein K, Zanger UM, Maser E, Wojnowski L. (2008). Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver. Drug Metab Dispos 36:2113-2120.
16. Kasukabe T, Okabe-Kado J, Kato N, Sassa T, Honma Y. (2005). Efects of combined treatment with rapamycin and cotylenin A, a novel diferentiation- inducing agent, on human breast carcinoma MCF-7 cells and xenografts. Breast Cancer Res 7:R1097-R1110.
17. Klucar J, Al-Rubeai M. (1997). G2 cell cycle arrest and apoptosis are induced in Burkitt's lymphoma cells by the anticancer agent oracin. FEBS Lett 400:127-130.
18. Leonard RC, Williams S, Tulpule A, Levine AM, Oliveros S. (2009). Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet). Breast 18:218-224.
19. Lewis MJ, Wiebe JP, Heathcote JG. (2004). Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma. BMC Cancer 4:27.
20. López de Cerain A, Marín A, Idoate MA, Tuñón MT, Bello J. (1999). Carbonyl reductase and NADPH cytochrome P450 reductase activities in human tumoral versus normal tissues. Eur J Cancer 35:320-324.
21. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. (1951). Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
22. Mordente A, Minotti G, Martorana GE, Silvestrini A, Giardina B, Meucci E. (2003). Anthracycline secondary alcohol metabolite formation in human or rabbit heart: biochemical aspects and pharmacologic implications. Biochem Pharmacol 66:989-998.
23. Ng R, Better N, Green MD. (2006). Anticancer agents and cardiotoxic-ity. Semin Oncol 33:2-14.
24. O'Connor R, O'Leary M, Ballot J, Collins CD, Kinsella P, Mager DE, Arnold RD, O'Driscoll L, Larkin A, Kennedy S, Fennelly D, Clynes M, Crown J. (2007). A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulin-dac, in combination with epirubicin in patients with advanced cancer. Cancer Chemother Pharmacol 59:79-87.
25. Oppermann U. (2007). Carbonyl reductases: the complex relationships of mammalian carbonyl-and quinone-reducing enzymes and their role in physiology. Annu Rev Pharmacol Toxicol 47:293-322.
26. Ravizza R, Gariboldi MB, Molteni R, Monti E. (2008). Linalool, a plant-derived monoterpene alcohol, reverses doxorubicin resistance in human breast adenocarcinoma cells. Oncol Rep 20:625-630.
27. Schimmel KJ, Richel DJ, van Den Brink RB, Guchelaar HJ. (2004). Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev 30:181-191.
28. Sereno M, Brunello A, Chiappori A, Barriuso J, Casado E, Belda C, de Castro J, Feliu J, González-Barón M. (2008). Cardiac toxic-ity: old and new issues in anti-cancer drugs. Clin Transl Oncol 10:35-46.
29. Simstein R, Burow M, Parker A, Weldon C, Beckman B. (2003). Apoptosis, chemoresistance, and breast cancer: insights from the MCF-7 cell model system. Exp Biol Med (Maywood) 228:995-1003.
30. Skarydová L, Skarka A, Novotná R, Zivná L, Martin HJ, Wsól V, Maser E. (2009a). Partial purifcation and characterization of a new human membrane-bound carbonyl reductase playing a role in the deac-tivation of the anticancer drug oracin. Toxicology 264:52-60.
31. Skarydová L, Zivná L, Xiong G, Maser E, Wsól V. (2009b). AKR1C3 as a potential target for the inhibitory efect of dietary favonoids. Chem Biol Interact 178:138-144.
32. Tan ML, Choong PF, Dass CR. (2009). Review: doxorubicin delivery systems based on chitosan for cancer therapy. J Pharm Pharmacol 61:131-142.
33. Tanaka M, Bateman R, Rauh D, Vaisberg E, Ramachandani S, Zhang C, Hansen KC, Burlingame AL, Trautman JK, Shokat KM, Adams CL. (2005). An unbiased cell morphology-based screen for new, biologically active small molecules. PLoS Biol 3:e128.
34. Trédan O, Galmarini CM, Patel K, Tannock IF. (2007). Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99:1441-1454.
35. Václavíková R, Kondrová E, Ehrlichová M, Boumendjel A, Kovár J, Stopka P, Soucek P, Gut I. (2008). Te efect of favonoid derivatives on doxorubicin transport and metabolism. Bioorg Med Chem 16:2034-2042.
36. Veitch ZW, Guo B, Hembruf SL, Bewick AJ, Heibein AD, Eng J, Cull S, Maclean DA, Parissenti AM. (2009). Induction of 1C aldoketore-ductases and other drug dose-dependent genes upon acquisition of anthracycline resistance. Pharmacogenet Genomics 19:477-488.
37. Zimmermann TJ, Niesen FH, Pilka ES, Knapp S, Oppermann U, Maier ME. (2009). Discovery of a potent and selective inhibitor for human carbonyl reductase 1 from propionate scanning applied to the macrolide zearalenone. Bioorg Med Chem 17:530-536.